-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OMN-6 in Hospital Acquired Pneumonia (HAP) Drug Details:OMN-6 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OMN-6 in Urinary Tract Infections Drug Details:OMN-6 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – K-170 in Graves Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - K-170 in Graves Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.K-170 in Graves DiseasesDrug Details:K-170 is under development for the treatment of Graves...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DISC-0974 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DISC-0974 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DISC-0974 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: DISC-0974 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emicizumab in Acquired Hemophilia A
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emicizumab in Acquired Hemophilia A report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Emicizumab in Acquired Hemophilia ADrug Details:Emicizumab (Hemlibra / RG-6013 / ACE-910) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMN-6 in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMN-6 in Acinetobacter Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OMN-6 in Acinetobacter InfectionsDrug Details:OMN-6 is under development for the treatment of multi-drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OMN-6
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OMN-6 Drug Details OMN-6 is under development for the treatment of multi-drug resistant Acinetobacter...
-
Product Insights
Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections – Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor...
-
Product Insights
Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Hospital Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development...
-
Product Insights
Ventilator Associated Pneumonia (VAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood). The Ventilator associated Pneumonia Drugs in Development market research report provides an in-depth analysis of the Ventilator associated...